Navigation Links
Mylan Declares Quarterly Preferred Stock Dividend
Date:7/31/2008

PITTSBURGH, July 31 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) today announced that in accordance with its 2.139 million preferred stock issuance, the company has declared its quarterly dividend of $16.25 per share (based on the annual dividend rate of 6.5% and a liquidation preference of $1,000.00 per share) payable on August 15, 2008, to holders of preferred stock of record as of August 1, 2008.

Mylan Inc., with operations in more than 90 countries, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest-and highest quality-product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's second largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies.


'/>"/>
SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Mylan Schedules Financial Results Conference Call and Live Webcast for the Second Quarter Fiscal 2008
2. Daniel E. Crookshank Joins Mylan as Vice President - Investor Relations
3. Mylan Announces Tentative FDA Approval for Generic Version of Antibiotic Zyvox(R) Tablets
4. Mylan Announces Final FDA Approval for Generic Version of Antidepressant Effexor(R)
5. Mylan Announces Tentative FDA Approval for Generic Version of Antihypertensive Avalide(R) Tablets
6. Mylan Wins Generic Prilosec(R) Patent Litigation
7. Mylan Inc., NATCO Pharma Ltd. To Collaborate on Worldwide Marketing and Distribution of Generic Copaxone(R)
8. Mylan Announces Final FDA Approval for Zaleplon Capsules
9. Mylan Inc. Acquires Central Eastern European Generics Businesses of Merck KGaA
10. Mylan Launches Paroxetine Hydrochloride Extended-Release Tablets
11. Mylan Schedules Financial Results Conference Call and Live Webcast for the First Quarter Fiscal 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... February 08, 2016 , ... ... Houma, LA, celebrates the beginning of a new charity campaign. As part of ... Appointed Special Advocates (CASA). In the belief that children deserve a voice, and ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... If you ... much to handle, you are not alone. According to the Center for Disease Control ... disease, stroke, type 2 diabetes and certain types of cancer, some of the leading ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... program serving the greater Venice, FL area, has initiated a fundraiser for a ... car accident just four days after Christmas. To support this beautiful child who ...
(Date:2/8/2016)... ... February 08, 2016 , ... Eating disorders and post-traumatic ... of women and men with eating disorders report a history of trauma, research ... development of an eating disorder. , At the 2016 iaedp Symposium, the ...
(Date:2/8/2016)... ... February 08, 2016 , ... The Association of ... AHCC and the Home Health and Hospice ICD-10 Transition Workgroup are working closely ... coding guidance and clarifications, to address concerns over the use of 'A' as ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... Feb. 8, 2016  HemaFlo Therapeutics, Inc. announced today that ... US Patent Number 9,119,880 covering the use of NephroFlow to ... , PhD, HemaFlo,s founder, said, "We are pleased to secure ... Dale Peterson , PhD, HemaFlo,s founder, said, "We are ... --> Dale Peterson , PhD, HemaFlo,s ...
(Date:2/8/2016)... Feb. 8, 2016  Sangamo BioSciences, Inc. (NASDAQ: ... editing, announced that the U.S. Food and Drug ... Drug (IND) application for SB-318, a single treatment ... Mucopolysaccharidosis Type I (MPS I). The SB-318 IND ... initiate a Phase 1/2 clinical study (SB-318-1502) designed ...
(Date:2/8/2016)... , 8. Februar 2016  LivaNova, ... heute eine Infografik mit dem Titel „Epilepsy ... Welt), mit der der Krankheit gegenüber ein ... dazu ermutigen soll, Medikamentenresistenz bei Epilepsie auf ... allgemeinen Diskussion zu machen. Mithilfe der neuen ...
Breaking Medicine Technology: